NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the impact of Natalizumab (Tysabri) therapy on sleep
efficiency, total sleep time and sleep latency, in Multiple Sclerosis (MS) patients receiving
Natalizumab for 6 months relative to baseline.